References
1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the american college of cardiology/american heart association task force on practice guidelines.Circulation . 2014;129(25 SUPPL. 1). doi:10.1161/01.cir.0000437738.63853.7a
2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol . 2019;73(24):e285-e350. doi:10.1016/j.jacc.2018.11.003
3. Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial.Lancet . 2002;360(9326):7-22. doi:10.1016/S0140-6736(02)09327-3
4. Tonkin A, Alyward P, Colquhoun D, et al. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. N Engl J Med . 1998;339(19):1349-1357. doi:10.1056/NEJM199811053391902
5. Sacks FM, Pfeffer MA, Moye LA, et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. N Engl J Med . 1996;335(14):1001-1009. doi:10.1056/NEJM199610033351401
6. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet . 2002;360(9346):1623-1630. doi:10.1016/S0140-6736(02)11600-X
7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. J Am Med Assoc . 1998;279(20):1615-1622. doi:10.1001/jama.279.20.1615
8. Lon S. Schneider MD et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med . 2004:687-696. doi:10.1056/NEJMoa1505949
9. La Rosa JC, Conti CR. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. ACC Cardiosource Rev J . 2006;15(5):97-99. doi:10.1016/s0749-4041(08)70417-2
10. Olsson AG, Ganz P, Oliver MF, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. Curr Cardiol Rep . 2001;3(5):384.
11. Kaul U, Varma J, Kahali D, Hiremath MS, Dani S, Dalal J, Ramchandran P, Rane R, Barkate H JC. Post-marketing study of clinical experience of atorvastatin 80 mg vs 40 mg in Indian patients with acute coronary syndrome- a randomized, multi-centre study (CURE-ACS). J Assoc Physicians India . 61(2):97-101.
12. Aljundi AHS, Mohammed SFK, Patel A, et al. Inotropic agents use in patients hospitalized with acute decompensated heart failure: a retrospective analysis from a 22-year registry in a Middle-Eastern Country (1991-2013). BMC Cardiovasc Disord . 2016;16:47. doi:10.1186/s12872-016-0223-5
13. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet . 2010;376(9753):1670-1681. doi:10.1016/S0140-6736(10)61350-5
14. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial.J Am Med Assoc . 2005;294(19):2437-2445. doi:10.1001/jama.294.19.2437